Longbio Pharma (Suzhou) Co (HKSE:01779) Total Receivables: HK$1.21 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01779 Longbio Pharma (Suzhou) Co Ltd HKSE:01779
10 GF Score
Price HK$113.00
View Full Analysis

What is Longbio Pharma (Suzhou) Co Total Receivables?

Longbio Pharma (Suzhou) Co HKSE:01779 +5.51% 10 Total Receivables is HK$1.21 Mil as of Dec. 2025. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100.

Longbio Pharma (Suzhou) Co's Total Receivables for the quarter that ended in Dec. 2025 was HK$1.21 Mil.

Longbio Pharma (Suzhou) Co Total Receivables Related Terms

Longbio Pharma (Suzhou) Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Longbio Pharma (Suzhou) Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co Total Receivables Chart

Longbio Pharma (Suzhou) Co Annual Data
Trend Dec24 Dec25
Total Receivables
0.06 1.21

Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24 Dec25
Total Receivables 0.06 1.21
HKSE:01779
10GF Score
Longbio Pharma (Suzhou) Co Ltd HKSE:01779
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longbio Pharma (Suzhou) Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of HK$1.21 Mil mean?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a Total Receivables of HK$1.21 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Longbio Pharma (Suzhou) Co and its competitors.
Is Longbio Pharma (Suzhou) Co's Total Receivables too high?
Longbio Pharma (Suzhou) Co's current Total Receivables is HK$1.21 Mil. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's Total Receivables compare to VRTX and REGN?
Longbio Pharma (Suzhou) Co's Total Receivables of HK$1.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Longbio Pharma (Suzhou) Co and its competitors. Longbio Pharma (Suzhou) Co's current Total Receivables is HK$1.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current Total Receivables of HK$1.21 Mil. The current Total Receivables is HK$1.21 Mil. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current Total Receivables is HK$1.21 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longbio Pharma (Suzhou) Co Business Description

Address No. 128 Yinhe Road, Dongnan Subdistrict, 5th Floor, Building F, Area A, Changshu City, Jiangsu Province, Suzhou, CHN
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score

Get the complete analysis for HKSE:01779

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$113.00
Price